Leadership

Officers

tony j. hunt

Chief Executive Officer

Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

Olivier Loeillot

President, Chief Commercial Officer

Olivier Loeillot joined Repligen in October 2023 as President and Chief Commercial Officer (CCO), where he has responsibility for driving the company’s commercial strategy and expanding the market impact of Repligen’s business units in bioprocessing. Mr. Loeillot joined Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets. Mr Loeillot previously served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. At Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. There, he was also instrumental in building and leading the Enterprise Solutions business, managing the Bioprocess ASIA business in Singapore, and directing the Genomics and Cellular Research division. Prior to Cytiva, Mr. Loeillot served a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. He also acted as Vice President of Sales for Lonza AG’s Custom Manufacturing Business and led the Microbial Biopharmaceuticals group. Mr. Loeillot earned his Master’s degree in Chemistry in 1993 from the European High Institute of Chemistry (EHICS) of Strasbourg, France, and later completed a Master’s of Business Administration (MBA) program at CESMA Business School of EM Lyon.

Jason K. Garland

Chief Financial Officer

Jason K. Garland joined Repligen in September 2023 as Chief Financial Officer (CFO), where he oversees financial operations for the company. He holds responsibility for all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting and risk management. Mr. Garland was previously with Integer Holdings Corporation, a medical device outsource (MDO) manufacturer, where he served for nearly five years as Executive Vice President and CFO, and assumed executive sponsorship of the company’s Business Process Excellence initiative focused on standardizing and optimizing all non-manufacturing processes. Prior to his role with Integer, Mr. Garland spent three years as Vice President and CFO for the global sales and supply divisions of Tiffany & Co., following nearly 20 years in various roles of increasing responsibility at GE. His rotations and achievements at GE culminated in several leadership positions including his role as CFO for GE Industrial Solutions; then a multi-billion dollar business with over 40 manufacturing sites. Mr. Garland serves on the Board and is Audit Chair for Acutus Medical, a publicly traded medical device company. He holds a B.S. in Chemical Engineering from the University of New Hampshire, and is Lean Six Sigma Black Belt certified.

jim bylund

Chief Operating Officer

James R. Bylund was named Chief Operating Officer of the Company in January 2022 and serves as the Company’s principal operating officer. He joined Repligen in March of 2020 as Senior Vice President, Global Operations and IT, overseeing all operations and IT functions on a global basis. Between March 2019 and March 2020, Mr. Bylund also worked in real estate at Inspire Development in Austin, Texas. Prior to joining Repligen, Mr. Bylund spent ten years at Thermo Fisher Scientific in a number of roles including Vice President and General Manager of the Single Use Technologies Business Unit and Vice President of Global Operations for the Bioproduction Division. Prior to joining Thermo Fisher, Mr. Bylund also worked for Fiserv (9 years) and Eli Lilly and Company (7 years) in a variety of leadership roles. He has significant experience in managing multiple operating sites across the globe and scaling operations to meet rapidly growing demand. Mr. Bylund is a passionate proponent of continuous improvement and has consistently demonstrated the ability to assemble and grow highly effective teams. He holds a B.S. in Accounting from Utah State University and an M.B.A. from Indiana University.

christine gebski

Senior Vice President, Filtration and Chromatography

Christine Gebski joined Repligen in May 2015 and currently serves as the Senior Vice President, Filtration and Chromatography where she oversees the general management and strategy of the Company’s upstream and downstream filtration and chromatography portfolio. Ms. Gebski also manages the Field Applications function within the Company, ensuring strong customer experience. Prior to joining Repligen, Ms. Gebski was head of the Chromatography Business Unit within the Bioproduction Division of Thermo Fisher Scientific. At Thermo Fisher she managed the Global Process Chromatography Applications and R&D functions for ten years. Before joining Thermo Fisher Scientific, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry, having held positions of increasing responsibility at Genzyme, TKT/Shire and EMD Pharmaceuticals. She has significant experience in downstream process development and engineering, technology transfer and validation across a variety of biological molecule classes and diagnostic reagents. She holds a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.

Ralf Kuriyel

Senior Vice President, Research and Development

Ralf Kuriyel joined Repligen in October 2016 as the Senior Vice President, Research and Development where he oversees the Company’s R&D efforts. Mr. Kuriyel was previously Vice President of Applications for the singleuse business unit within the Life Sciences division of Pall Corporation (“Pall”), whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. Mr. Kuriyel received a B.S. and an M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed his coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.

Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

Olivier Loeillot joined Repligen in October 2023 as President and Chief Commercial Officer (CCO), where he has responsibility for driving the company’s commercial strategy and expanding the market impact of Repligen’s business units in bioprocessing. Mr. Loeillot joined Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets. Mr Loeillot previously served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. At Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. There, he was also instrumental in building and leading the Enterprise Solutions business, managing the Bioprocess ASIA business in Singapore, and directing the Genomics and Cellular Research division. Prior to Cytiva, Mr. Loeillot served a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. He also acted as Vice President of Sales for Lonza AG’s Custom Manufacturing Business and led the Microbial Biopharmaceuticals group. Mr. Loeillot earned his Master’s degree in Chemistry in 1993 from the European High Institute of Chemistry (EHICS) of Strasbourg, France, and later completed a Master’s of Business Administration (MBA) program at CESMA Business School of EM Lyon.

Jason K. Garland joined Repligen in September 2023 as Chief Financial Officer (CFO), where he oversees financial operations for the company. He holds responsibility for all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting and risk management. Mr. Garland was previously with Integer Holdings Corporation, a medical device outsource (MDO) manufacturer, where he served for nearly five years as Executive Vice President and CFO, and assumed executive sponsorship of the company’s Business Process Excellence initiative focused on standardizing and optimizing all non-manufacturing processes. Prior to his role with Integer, Mr. Garland spent three years as Vice President and CFO for the global sales and supply divisions of Tiffany & Co., following nearly 20 years in various roles of increasing responsibility at GE. His rotations and achievements at GE culminated in several leadership positions including his role as CFO for GE Industrial Solutions; then a multi-billion dollar business with over 40 manufacturing sites. Mr. Garland serves on the Board and is Audit Chair for Acutus Medical, a publicly traded medical device company. He holds a B.S. in Chemical Engineering from the University of New Hampshire, and is Lean Six Sigma Black Belt certified.

James R. Bylund was named Chief Operating Officer of the Company in January 2022 and serves as the Company’s principal operating officer. He joined Repligen in March of 2020 as Senior Vice President, Global Operations and IT, overseeing all operations and IT functions on a global basis. Between March 2019 and March 2020, Mr. Bylund also worked in real estate at Inspire Development in Austin, Texas. Prior to joining Repligen, Mr. Bylund spent ten years at Thermo Fisher Scientific in a number of roles including Vice President and General Manager of the Single Use Technologies Business Unit and Vice President of Global Operations for the Bioproduction Division. Prior to joining Thermo Fisher, Mr. Bylund also worked for Fiserv (9 years) and Eli Lilly and Company (7 years) in a variety of leadership roles. He has significant experience in managing multiple operating sites across the globe and scaling operations to meet rapidly growing demand. Mr. Bylund is a passionate proponent of continuous improvement and has consistently demonstrated the ability to assemble and grow highly effective teams. He holds a B.S. in Accounting from Utah State University and an M.B.A. from Indiana University.

Christine Gebski joined Repligen in May 2015 and currently serves as the Senior Vice President, Filtration and Chromatography where she oversees the general management and strategy of the Company’s upstream and downstream filtration and chromatography portfolio. Ms. Gebski also manages the Field Applications function within the Company, ensuring strong customer experience. Prior to joining Repligen, Ms. Gebski was head of the Chromatography Business Unit within the Bioproduction Division of Thermo Fisher Scientific. At Thermo Fisher she managed the Global Process Chromatography Applications and R&D functions for ten years. Before joining Thermo Fisher Scientific, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry, having held positions of increasing responsibility at Genzyme, TKT/Shire and EMD Pharmaceuticals. She has significant experience in downstream process development and engineering, technology transfer and validation across a variety of biological molecule classes and diagnostic reagents. She holds a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.

Ralf Kuriyel joined Repligen in October 2016 as the Senior Vice President, Research and Development where he oversees the Company’s R&D efforts. Mr. Kuriyel was previously Vice President of Applications for the singleuse business unit within the Life Sciences division of Pall Corporation (“Pall”), whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. Mr. Kuriyel received a B.S. and an M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed his coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.

Functional Leaders

Surendra Balekai

Vice President of Fluid Management

Surendra Balekai was named Vice President for Repligen’s Fluid Management Business in January 2024. He is responsible for business management, strategy and expanding market for Fluid Management portfolio. Mr.Balekai joined Repligen in 2019 as Director for Systems business and advanced to Sr. Director in 2021 responsible for TFF/  Chromatography systems & related consumables business. Prior to joining Repligen, Mr. Balekai spent ten years at Thermo Fisher Scientific in several roles as Single Use Technical leader – Asia Pacific, Commercial leader for Bioproduction business in Singapore and moved to USA for Global Product Management responsibilities. Earlier Mr. Balekai held various positions of increasing responsibilities at Sartorius Stedim for eight years and Millipore in India for five years. Mr. Balekai earned his degree in Chemical Engineering, later completed Master’s of Business Administration (MBA) program from Jack Welch Management Institute and completed Certificate of Specialization in Strategy from Harvard Business school online.

Kimberly Cornwell

General Counsel

General Counsel

Leslie Galvin

Vice President, Human Resources

Leslie joined Repligen in May 2022, initially leading the US and European HR teams supporting the COO global organization. In September 2022, she moved into the Global Head, Human Resources role where she is responsible for leading Repligen’s overall human resources function including strategy, global talent acquisition, employee development, diversity & inclusion, and HR operations. Leslie has over twenty years of global HR leadership experience in the life sciences, healthcare, and high-tech manufacturing industries. Leslie earned her bachelor’s degree in Human Resources and Industrial and Labor Relations from Bowling Green State University, her M.S.A. in Human Resources from Central Michigan University and her J.D. with a concentration in Employment Law from Capital University.   

Jaime M. Humara, Ph.D.

Senior Vice President, Marketing

Dr. Jaime M. Humara joined Repligen in November 2022 and currently serves as the Senior Vice President of Global Marketing, overseeing the corporate, digital and strategic marketing functions for the organization. Prior to joining Repligen, Dr. Humara spent 3.5 years as Vice President of Worldwide Marketing for the Biosciences unit of Beckton Dickinson. During his tenure, he built the downstream strategic marketing function for the business unit and hired and led a team of 28 marketing professionals with responsibilities for web and eCommerce, global demand generation campaigns, scientific marketing, and analytics for the entire $1.4B portfolio of research and clinical solutions for immunology, reporting to both the President of BD Biosciences and the Chief Marketing Officer of BD.

Prior to joining BD, Dr. Humara was the Vice President of Global Marketing for the Life Science Group at Bio-Rad, where he led a team of marketing professionals with global responsibilities for upstream, downstream, and marketing communications and brand for key businesses that hold leadership positions in protein quantification and imaging, protein purification, gene expression and cell biology.

Before, he served as the Director of Global Strategic Marketing for Beckman Coulter Diagnostics and led a multi-regional team responsible for the global launch of a new CE-mark molecular diagnostics platform and assay portfolio, as well as being instrumental to Danaher’s acquisition of Cepheid.

Dr. Humara started his marketing career in the early 2000’s at Thermo Fisher Scientific (formerly Life Technologies), where he held multiple global and regional marketing roles, M&A, and integration during his 9 years with the firm.

Dr. Humara earned his doctorate in Plant Biotechnology in 1994, and has a BS in Biological Sciences, both from the University of Oviedo, Spain.

Kola Otitoju

Senior Vice President, Strategy and Business Development

Kola Otitoju joined Repligen in 2020 as Senior Vice President of Strategy and Business Development. He is responsible for leading the development and execution of the Repligen growth strategy including partnerships, licensing, investments and mergers and acquisitions. Mr. Otitoju brings a wealth of experience in strategic planning and execution having led multiple transactions in excess of $100BN through his tenures in Investment Banking M&A at Credit Suisse and Banc of America Securities (8 years), large publicly traded corporations including Baxter and GE Healthcare (6 years), and private equity-backed companies like Candela Medical with Apax Partners (3 years). He also brings a strong technical background having been an Electrical Engineer earlier in his career. Mr. Otitoju has Masters Degrees in Business Administration from Harvard Business School and Electrical Engineering from Cornell University, in addition to a Bachelor's Degree in Information Systems Engineering from Imperial College London.

Surendra Balekai was named Vice President for Repligen’s Fluid Management Business in January 2024. He is responsible for business management, strategy and expanding market for Fluid Management portfolio. Mr.Balekai joined Repligen in 2019 as Director for Systems business and advanced to Sr. Director in 2021 responsible for TFF/  Chromatography systems & related consumables business. Prior to joining Repligen, Mr. Balekai spent ten years at Thermo Fisher Scientific in several roles as Single Use Technical leader – Asia Pacific, Commercial leader for Bioproduction business in Singapore and moved to USA for Global Product Management responsibilities. Earlier Mr. Balekai held various positions of increasing responsibilities at Sartorius Stedim for eight years and Millipore in India for five years. Mr. Balekai earned his degree in Chemical Engineering, later completed Master’s of Business Administration (MBA) program from Jack Welch Management Institute and completed Certificate of Specialization in Strategy from Harvard Business school online.

General Counsel

Leslie joined Repligen in May 2022, initially leading the US and European HR teams supporting the COO global organization. In September 2022, she moved into the Global Head, Human Resources role where she is responsible for leading Repligen’s overall human resources function including strategy, global talent acquisition, employee development, diversity & inclusion, and HR operations. Leslie has over twenty years of global HR leadership experience in the life sciences, healthcare, and high-tech manufacturing industries. Leslie earned her bachelor’s degree in Human Resources and Industrial and Labor Relations from Bowling Green State University, her M.S.A. in Human Resources from Central Michigan University and her J.D. with a concentration in Employment Law from Capital University.   

Dr. Jaime M. Humara joined Repligen in November 2022 and currently serves as the Senior Vice President of Global Marketing, overseeing the corporate, digital and strategic marketing functions for the organization. Prior to joining Repligen, Dr. Humara spent 3.5 years as Vice President of Worldwide Marketing for the Biosciences unit of Beckton Dickinson. During his tenure, he built the downstream strategic marketing function for the business unit and hired and led a team of 28 marketing professionals with responsibilities for web and eCommerce, global demand generation campaigns, scientific marketing, and analytics for the entire $1.4B portfolio of research and clinical solutions for immunology, reporting to both the President of BD Biosciences and the Chief Marketing Officer of BD.

Prior to joining BD, Dr. Humara was the Vice President of Global Marketing for the Life Science Group at Bio-Rad, where he led a team of marketing professionals with global responsibilities for upstream, downstream, and marketing communications and brand for key businesses that hold leadership positions in protein quantification and imaging, protein purification, gene expression and cell biology.

Before, he served as the Director of Global Strategic Marketing for Beckman Coulter Diagnostics and led a multi-regional team responsible for the global launch of a new CE-mark molecular diagnostics platform and assay portfolio, as well as being instrumental to Danaher’s acquisition of Cepheid.

Dr. Humara started his marketing career in the early 2000’s at Thermo Fisher Scientific (formerly Life Technologies), where he held multiple global and regional marketing roles, M&A, and integration during his 9 years with the firm.

Dr. Humara earned his doctorate in Plant Biotechnology in 1994, and has a BS in Biological Sciences, both from the University of Oviedo, Spain.

Kola Otitoju joined Repligen in 2020 as Senior Vice President of Strategy and Business Development. He is responsible for leading the development and execution of the Repligen growth strategy including partnerships, licensing, investments and mergers and acquisitions. Mr. Otitoju brings a wealth of experience in strategic planning and execution having led multiple transactions in excess of $100BN through his tenures in Investment Banking M&A at Credit Suisse and Banc of America Securities (8 years), large publicly traded corporations including Baxter and GE Healthcare (6 years), and private equity-backed companies like Candela Medical with Apax Partners (3 years). He also brings a strong technical background having been an Electrical Engineer earlier in his career. Mr. Otitoju has Masters Degrees in Business Administration from Harvard Business School and Electrical Engineering from Cornell University, in addition to a Bachelor's Degree in Information Systems Engineering from Imperial College London.

Keith Lee Robinson

Chief Information Officer

A Jamaican native, Keith has over 2 decades of experience consulting on and managing information systems and information technology in multiple industries in the United States, Canada and the Caribbean. He has been employed at Repligen since 2015 in different IT leadership roles, building and leading a global IT organization. As Chief Information Officer, Keith’s main priorities are to enable and optimize business productivity, drive technological innovation, protect the company’s digital assets and to run an efficient IT organization Keith earned a Master’s of Science degree in Management Information Systems from the University of the West Indies, Jamaica.

Mark Salerno

Vice President And Global Head, Process Analytics

Mark Salerno joined Repligen as part of the C Technologies, Inc. acquisition in 2019 and currently serves as Vice President and Global Head of the Process Analytics business unit. Mr. Salerno brings over twenty-five years of experience to Repligen, where he is responsible for R&D, Operations, Quality and Commercial activities leading the team that is working to expanding the PAT portfolio to bring disruptive and enabling technologies to the bio-pharmaceutical industry.  Mr. Salerno is an inventor of numerous patents on fiber optic solutions and instrumentation, most notably the CTech™ SoloVPE®, CTech™ FlowVPX® and variable pathlength technologies.   He holds a bachelor’s degree in mechanical engineering from the University of Notre Dame and an MBA in from the Seton Hall University Stillman School of Business. 

Greg Titus

Senior Vice President, Commercial Development

Greg Titus joined Repligen in March 2023 and currently serves as Senior Vice President Commercial Development. Mr. Titus is responsible for developing and implementing Repligen corporate commercial strategy, as well as developing and leading top-down sales initiatives across the global commercial organization. He brings over 30 years of life sciences industry experience to Repligen, including development and leadership of bioprocessing commercial strategies and teams within the US and globally. Prior to joining Repligen, Mr. Titus spent a combined 13 years with Cytiva (a Danaher company and previously GE Healthcare Life Sciences), including his most recent role was as General Manager, Global Strategic Accounts and Advanced Therapies. He also spent 17 years at EMD Millipore (now Millipore Sigma), leading Key Account Management programs and Business Development. Mr. Titus began his career in various service engineering, technical specialist and sales roles that lead to more strategic and operational opportunities. Greg has a degree in Electrical & Computer Engineering from Heald Institute of Technology and specialty certificates from Harvard Business “Advanced Negotiations” and El Camino College Los Angeles “The Art of Negotiations”.  He grew-up and currently lives in Napa Valley California, and is the founder & winemaker of Ominous Cellars.

Neil Whitfield

Vice President, Sales

Neil Whitfield joined Repligen in May 2020 as Vice President, Commercial Development and in October 2022 took the role of Vice President, Global Sales. Mr. Whitfield is responsible for building and developing a world class sales organization that executes effectively and delivers a positive customer experience. Before joining Repligen, Neil worked at Thermo Fisher Scientific Inc. where he led the commercial organization for the Bioproduction Division in EMEA for 9 years and successfully integrated the commercial organizations of Life Technologies and Thermo Fisher Scientific into one cohesive team. Prior to that, Mr. Whitfield spent 25 years at Applied Biosystems in various operational roles, before moving into the commercial organization to lead the Applied Markets Division in Europe and Middle East for Process Analytics, Food Pathogens and Animal Diagnostics. Mr. Whitfield holds a Higher National qualification in Chemistry from the University of Manchester, U.K. and a Post Graduate Diploma in Business Management from Liverpool University, U.K.

A Jamaican native, Keith has over 2 decades of experience consulting on and managing information systems and information technology in multiple industries in the United States, Canada and the Caribbean. He has been employed at Repligen since 2015 in different IT leadership roles, building and leading a global IT organization. As Chief Information Officer, Keith’s main priorities are to enable and optimize business productivity, drive technological innovation, protect the company’s digital assets and to run an efficient IT organization Keith earned a Master’s of Science degree in Management Information Systems from the University of the West Indies, Jamaica.

Mark Salerno joined Repligen as part of the C Technologies, Inc. acquisition in 2019 and currently serves as Vice President and Global Head of the Process Analytics business unit. Mr. Salerno brings over twenty-five years of experience to Repligen, where he is responsible for R&D, Operations, Quality and Commercial activities leading the team that is working to expanding the PAT portfolio to bring disruptive and enabling technologies to the bio-pharmaceutical industry.  Mr. Salerno is an inventor of numerous patents on fiber optic solutions and instrumentation, most notably the CTech™ SoloVPE®, CTech™ FlowVPX® and variable pathlength technologies.   He holds a bachelor’s degree in mechanical engineering from the University of Notre Dame and an MBA in from the Seton Hall University Stillman School of Business. 

Greg Titus joined Repligen in March 2023 and currently serves as Senior Vice President Commercial Development. Mr. Titus is responsible for developing and implementing Repligen corporate commercial strategy, as well as developing and leading top-down sales initiatives across the global commercial organization. He brings over 30 years of life sciences industry experience to Repligen, including development and leadership of bioprocessing commercial strategies and teams within the US and globally. Prior to joining Repligen, Mr. Titus spent a combined 13 years with Cytiva (a Danaher company and previously GE Healthcare Life Sciences), including his most recent role was as General Manager, Global Strategic Accounts and Advanced Therapies. He also spent 17 years at EMD Millipore (now Millipore Sigma), leading Key Account Management programs and Business Development. Mr. Titus began his career in various service engineering, technical specialist and sales roles that lead to more strategic and operational opportunities. Greg has a degree in Electrical & Computer Engineering from Heald Institute of Technology and specialty certificates from Harvard Business “Advanced Negotiations” and El Camino College Los Angeles “The Art of Negotiations”.  He grew-up and currently lives in Napa Valley California, and is the founder & winemaker of Ominous Cellars.

Neil Whitfield joined Repligen in May 2020 as Vice President, Commercial Development and in October 2022 took the role of Vice President, Global Sales. Mr. Whitfield is responsible for building and developing a world class sales organization that executes effectively and delivers a positive customer experience. Before joining Repligen, Neil worked at Thermo Fisher Scientific Inc. where he led the commercial organization for the Bioproduction Division in EMEA for 9 years and successfully integrated the commercial organizations of Life Technologies and Thermo Fisher Scientific into one cohesive team. Prior to that, Mr. Whitfield spent 25 years at Applied Biosystems in various operational roles, before moving into the commercial organization to lead the Applied Markets Division in Europe and Middle East for Process Analytics, Food Pathogens and Animal Diagnostics. Mr. Whitfield holds a Higher National qualification in Chemistry from the University of Manchester, U.K. and a Post Graduate Diploma in Business Management from Liverpool University, U.K.

Board of Directors

01

Chairperson

Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves on the board of directors of two publicly traded companies: Vaccitech Limited and Medicenna Therapeutics Corp, one private company, JPA Health, and one not-for-profit company, Medicines 360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.

02

Nicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 30 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen Inc. (“Biogen”) for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. Mr. Barthelemy also serves on the board of directors of three privately held companies: Biocare Medical LLC, NanoCellect Biomedical, and Slingshot Biosciences. He also serves as an advisor to Warburg Pincus, a private equity firm. Mr. Barthelemy previously served as a board member of Twist Bioscience, 908 Devices Inc. and Standard BioTools, Inc. (previously Fluidigm Corporation). Mr. Barthelemy received a M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.

03

Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

04

Konstantin Konstantinov, Ph.D., has served as a director of Repligen since May 2022. He has also been a member of our Scientific Advisory Board since March 2016. Dr. Konstantinov is currently Chief Technology Officer at Codiak BioSciences (“Codiak”), where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Before joining Codiak, Dr. Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

08

Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus joins the Board with over 25 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation (“Millipore”), where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA (“Merck”) in 2010. He is an active board leader, currently serving two other public companies: as Lead Director for precision health technology company Quanterix Corporation and as a board member for mass cytometry player Standard BioTools, Inc. (previously Fluidigm Corporation). He also serves on the boards of three private companies: Unchained Labs, Emulate Inc. and Ultivue Inc. Dr. Madaus is currently a senior operating executive at The Carlyle Group (since 2019), a multinational private equity and asset management services company. He previously served as Chairman and CEO at Ortho-Clinical Diagnostics from 2014 to 2019. His tenure with biopharmaceutical and diagnostic industry leader Roche Holding AG (“Roche”) from 1996 to 2004 included his position from 2000 to 2004 as President and CEO, N.A. of Roche Diagnostics Corp. Dr. Madaus began his career as a veterinarian, before joining global pharmaceutical and diagnostic company Boehringer Mannheim Corporation (“Boehringer”). While at Boehringer, he held sales, marketing and product management roles from 1989 to 1996, until his move into general management coincided with the company’s acquisition by Roche in 1996. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany. Dr. Madaus’ qualifications to sit on the Company’s Board include his extensive bioprocessing and biopharmaceutical industry experience, especially in the areas of strategy, mergers and acquisitions, and commercial operations.

05

Carrie Eglinton Manner has served as a director of Repligen since June 2020. She brings to the director role over 25 years of leadership experience across multiple disciplines. Ms. Eglinton Manner currently serves as President and CEO of OraSure Technologies, Inc. (“OraSure”), which she joined in June 2022. OraSure is a leader in the development, manufacture and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular service solutions designed to discover and detect critical medical conditions. Prior to OraSure, Ms. Eglinton Manner served as Senior Vice President, Advanced & General Diagnostics and Clinical Solutions at Quest Diagnostics (“Quest”), which she joined in 2017. In her role at Quest, Ms. Eglinton Manner was responsible for value creation across the company’s $10 billion clinical portfolio, driving innovation in R&D, along with partnerships and acquisitions. She helped accelerate growth in Quest’s $2 billion Advanced Diagnostics portfolio, which included its specialty molecular and genetic offerings, along with Quest’s global and pharmaceutical services businesses. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. In addition to the Repligen Board, Ms. Eglinton Manner serves as board director for the not-for-profit Thrive Networks, focused on advancing women and building healthy, resilient communities. Ms. Eglinton Manner holds a B.S. in Mechanical Engineering from the University of Notre Dame. Ms. Eglinton Manner’s qualifications to sit on the Company’s Board include her track record of delivering business expansion and profitability for rapidly growing global businesses, including her experience with integrating acquisitions and building operations excellence, with a commitment to quality and process improvements.

06

Rohin Mhatre, Ph.D., was appointed to the Board in March 2020. Dr. Mhatre brings over 25 years of relevant experience to the director role, including his current position since January 2017, as Senior Vice President, Product and Technology Development at Biogen. He has held numerous other roles of increasing responsibility within Biogen, which he joined in 1996, including six years as Vice President of Biopharmaceutical Development, where he led a 300-member team responsible for cell line, cell culture, purification and device development. Earlier in Dr. Mhatre’s career at Biogen, he focused on building out analytical development and technical services. Prior to Biogen, Dr. Mhatre led the purification and applications group at Applied BioSystems (formerly Perspective Biosystems). Dr. Mhatre holds a Ph.D. in Chemistry from Northeastern University. Dr. Mhatre’s qualifications to sit on the Company’s Board include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows.

07

Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc. (“Hologic”), a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venture-backed single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir also serves on the board of directors of two publicly traded companies: medical technology company, Neuronetics, Inc., and life science company G1 Therapeutics, Inc., and one privately held company: medical device company Impulse Dynamics Limited. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant (inactive since 2022) with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S. from Bentley University and an M.B.A. from Harvard University. Mr. Muir’s qualifications to sit on Repligen’s Board include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.

Scientific Advisory Board

01

Richard D. Braatz is the Edwin R. Gilliland Professor at the Massachusetts Institute of Technology (MIT) where he does research in process data analytics, design, and control of advanced manufacturing systems. He received MS and Ph.D. from the California Institute of Technology and was the Millennium Chair and Professor at the University of Illinois at Urbana-Champaign and a Visiting Scholar at Harvard University before moving to MIT. He has consulted and/or collaborated with more than 30 companies including Merck, Novartis, Pfizer, Amgen, Biogen, and Bristol-Myers Squibb. He is a member of the National Academy of Engineering.

02

Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering, Emeritus in the Department of Chemical Engineering at MIT and founding Faculty Director, Emeritus of the Deshpande Center for Technological Innovation at MIT. With a BS in chemical engineering from the University of Pennsylvania and an SM and Ph.D. in Biochemical engineering from MIT, he has spent his professional career on the MIT faculty. He is an expert in process design, upstream and downstream bioprocess development, and manufacturing of pharmaceutical and biological products.  Prof. Cooney has served as a consultant to or board member of multiple biotech and pharmaceutical companies and is chairman of Repligen’s Scientific Advisory Board.

03

Dr. Cramer is the William Weightman Walker Professor at Rensselaer Polytechnic Institute and is known for his contributions to the separation of complex biological products and the development of chromatographic materials, processes and predictive tools for enabling their biomanufacturing. In addition, he has made seminal contributions to the molecular understanding of the interactions that create unique selectivities in these separation systems. His lab is currently conducting research on several areas related to protein-surface interactions including prediction of protein binding affinity and multiscale modeling of chromatographic systems, development of efficient antibody and bispecific antibody separation systems, fundamental studies in multimodal chromatography, multilevel automated peptide synthesis/screening system for design of affinity peptides, smart biopolymer affinity precipitation systems, biophysics of protein interactions with surfaces, ligands and proteins, platformable strategies for effective removal of process HCPs and integrated semi-continuous biomanufacturing processes. He was the editor of Separation Science and Technology for 20 years and has been awarded the Alan S. Michaels Award for the Recovery of Biological Products (ACS Division of Biochemical Technology) and the ACS National Award in Separation Science and Technology. He was also awarded Rensselaer’s Distinguished Faculty Award as well as the School of Engineering Outstanding Professor and Research Excellence Awards. Dr. Cramer has been elected a fellow of the American Association for the Advancement of Science, American Institute of Chemical Engineers, the American Chemical Society and the American Institute for Medical and Biological Engineering.

05

Konstantin Konstantinov, Ph.D., has been a member of our Scientific Advisory Board since March 2016. He also serves as a director of Repligen since May 2022. Dr. Konstantinov is currently Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

06

J. Christopher Love is the Raymond A. (1921) and Helen E. St. Laurent Professor of Chemical Engineering and member of the Koch Institute for Integrative Cancer Research at MIT. In addition, he is an associate member at the Eli and Edythe L. Broad Institute, and at the Ragon Institute of MGH, MIT, and Harvard. Prof. Love received his Ph.D. in 2004 in physical chemistry at Harvard University. He extended his research into immunology at Harvard Medical School from 2004-2005, and at the Immune Disease Institute from 2005-2007. His research centers on using simple microsystems to monitor cells from clinical samples in chronic human diseases, and on developing new approaches to manufacturing biologic drugs and vaccines efficiently and affordably.  Prof. Love was named a Dana Scholar for Human Immunology and a Keck Distinguished Young Scholar in Medical Research in 2009, one of Popular Science’s Brilliant 10 in 2010, and also a Camille Dreyfus Teacher-Scholar. At MIT, he is the Director of the Alternative Host Consortium, a unique MIT-Industry partnership advancing new manufacturing hosts for biopharmaceuticals and vaccines. He previously served as a Distinguished Engineer in Residence at Biogen (2015-2016), and also consults for several biotechnology and biopharmaceutical companies, including three current start-ups based on technologies from his lab at MIT (Honeycomb, OneCyte, and Sunflower).

07

Hubert Scoble’s, Ph.D., professional career spans four decades in the biotechnology and biopharmaceutical industry. The majority of his career has focused on drug substance and drug product biopharmaceutical development and clinical and commercial production operations with Genetics Institute, Wyeth, Pfizer and Sanofi. He has had responsibility for all aspects of pre- and post-approval CMC biopharma drug development, technical portfolio management and product and technical strategy development and deployment. Throughout his career he has been directly involved with the regulatory approval of 20+ commercial biopharma products.

Dr. Scoble received his Ph.D. in Analytical Chemistry from the University of Rhode Island which was followed by a Postdoctoral Fellowship in the Department of Chemistry at MIT (K. Biemann laboratory). He currently serves as a CMC, technical and operational strategy consultant to large and smaller biopharmaceutical companies and also serves on the Scientific/Technical Advisory Boards for several companies.